Epizyme eyes lucrative use for newly-launched Tazverik

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.

NICE rejects MSD/Pfizer's combination in untreated kidney ca...

NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) in untreated kidney cancer, citing uncertainties about its lon

Xtandi takes fight to prostate cancer rivals with survival d...

GSK sets out plans to split following full year earnings mis...

GlaxoSmithKline has set out a two-year plan to split itself in two after missing its earnings targets in full year results and predicting a decline in earnings this year.

2nd Digital Health for Pharma (DH4P)

The Evolution Road and ExL Events

Pfizer disappoints in Q4 after Ibrance misses sales targets

Pfizer kicked off big pharma’s final results season with a disappointing readout that sent its share price ticking down, with breast cancer drug Ibrance missing sales expectations and off-p